Venous Ethanol Ablation as the Sole Treatment for Intramural Ventricular Arrhythmias.

POSTER PRESENTATIONS

Sinus arrest during radiofrequency ablation from the inferoseptal process of the left ventricle: Proposed mechanisms of an uncommon finding

ORAL PRESENTATION

A 2F epicardial electrode–guided ablation from left coronary cusp for substrates of left ventricular summit tachycardia

Background Insertable cardiac monitors (ICM) have the capability to continuously monitor premature ventricular contraction (PVC) burden over time [1] as well as detect ventricular tachycardia and fibrillation (VT/VF). Objective We investigated the association of PVC burden with incidence of VT/VF in a large real-world cohort of patients implanted with ICMs. Methods Patients implanted with an ICM for various reasons for monitoring and PVC detection turned on were included from the ICM manufacturer's de-identified data warehouse. Patients were included if they had at least 90 days of PVC burden follow-up. Tachycardia episodes that were detected by the ICM were first classified as VT/VF, SVT, or oversensing using an artificial intelligence (AI) model that was pre-trained using over 60,000 manually adjudicated ICM detected tachycardia episodes. If the AI model output probability for VT/VF was greater than 0.2, then those episodes were manually adjudicated for incidence of non-induced spontaneous VT/VF. The PVC burden trends recorded by the device were divided into 4 mutually exclusive patient groups: (1) 0% PVC burden on all days, (2) 1-4% PVC burden on ≥1 day, (3) 5-9% PVC burden on ≥1 day, and (4) >10% PVC on ≥1 day. The incidence rate of spontaneous VT/VF was compared between the PVC burden patient groups using a Generalized Estimating Equations model with negative binomial distribution. Time to first spontaneous VT/VF occurrence after the first day of occurrence of PVC burden for the respective PVC burden groups were estimated using Kaplan-Meier analysis and the groups were compared using the Cox proportional hazards model. Results A total of 5,521 patients were included in the analysis. Patients had an average age of 69±15 years and 49.8% being males. There was a total of 33,393 tachycardia episodes from 2,641 patients that were detected by the ICM. After AI model probability-based adjudications, 691 spontaneous VT/VF episodes were identified from 277 patients. Patients with ≥1 day of PVC burden of 1-4%, 5-9%, and ≥10% were associated with 2.9, 7.3, and 7.8 times increased incidence rate of VT/VF episodes during follow-up period relative to patients with 0% PVC burden on all days of follow-up (Figure A). Kaplan Meier curves for incidence of first spontaneous VT/VF episode for the four groups following occurrence of the first day of qualifying PVC burden for the respective groups are shown in figure B. Patients with a day of PVC burden ≥10% were 3.5 times more likely to develop VT/VF in the future compared to patients with 0% PVC burden on all days. Conclusion Days with high PVC burden, as detected by an ICM with continuous PVC detection capability, were associated with increased risk of VT/VF events in a group of real-world patients implanted with ICMs. PVC burden measured by ICMs may be a risk stratification tool for further investigation to prevent sudden cardiac arrest.

Metastases to the cardiac ventricles are rare and, unfortunately, often follow a rapidly fatal course.1,2 Occasionally, they cause symptomatic ventricular arrhythmias (VAs) for which limited therapeutic options exist, such as antiarrhythmic drugs, whereas the use of catheter ablation, to our knowledge, has never been reported to date. We present the case of a 27-year-old man with a metastatic tumor in the left ventricle and intractable malignant VAs. In February 2009, the patient had been diagnosed with a gluteal sarcoma and initially treated with combined chemotherapy (including anthracyclines) and radiation. Since December 2009, a mild reduction in left ventricular ejection fraction (45%) was detected, and since January 2010, frequent monomorphic premature ventricular contractions (PVCs) and nonsustained ventricular tachycardias (VTs) were documented. Treatment with amiodarone proved helpful, and no life-threatening VAs could be induced on standard electrophysiological study.3 Since April 2010, however, the patient suffered from multiple drug-refractory episodes of sustained VT and ventricular fibrillation, requiring several direct current shocks (Figure 1). His left ventricular ejection fraction had remained stable. Electrical storm resulted in immediate hemodynamic instability and dramatically affected his quality of life. The patient was referred to our institution, where multiple antiarrhythmic drug combinations were tested, both orally and intravenously, allowing a relative stabilization of cardiac rhythm. Cardiac MRI showed a T2-hyperintense, weakly gadolinium-enhanced area at the basis of the anterior papillary muscle, compatible with metastatic infiltration (Figure 2, online-only Data Supplement Movie 1). An oncology consultation hypothesized a life expectancy of <6 months. After about 2 weeks, the recurrence of multiple episodes of VT and ventricular fibrillation required intensive care treatment with deep sedation and assisted ventilation, but still VAs could not be controlled. Thus, a repeat electrophysiological evaluation and radiofrequency …

Guidewire ablation of epicardial ventricular arrhythmia within the coronary venous system: A case report

BackgroundAlthough nonsustained ventricular tachycardia (NSVT) is a risk factor for sudden cardiac death in hypertrophic‐cardiomyopathy (HCM), the impact of premature ventricular contraction (PVC) burden, in the absence of NSVT, is not well‐known.HypothesisPVC burden may be associated with myocardial fibrosis and genetic mutations in patients with HCM.MethodsOf the 212 patients prospectively enrolled to the HCM registry of genetics, 84 were evaluated with both cardiac magnetic resonance, 24‐hour Holter monitoring and genetic analysis. Among them, 71 patients have not been diagnosed with NSVT.ResultsPatients with NSVT (n = 13) had a higher late gadolinium enhancement (LGE) amount, extracellular volume fraction (ECV), and prevalence of sarcomere mutations compared with patients without NSVT. Among patients without NSVT, those with LGE (n = 46) had a higher total PVC (109 ± 332 vs 7 ± 13, P = .003) and PVC burden (0.114 ± 0.225 vs 0.008 ± 0.014%, P = .003) during 24‐hour Holter monitoring compared with others. The %LGE and global ECV were correlated with PVC burden (r = 0.377, P = .001; r = 0.401, P = .001). The optimal cutoff value for PVC number for LGE was 45 (37.0% and 100% sensitivity and specificity, respectively) with 0.733 of the area under the receiver operating characteristic‐curve (P < .001). Thick filament gene mutation was more prevalent in the higher PVC burden group (41.2% vs 16.7%, P = .048).ConclusionTotal PVC burden is significantly related to increase in myocardial fibrosis in HCM patients without NSVT.

The UNIFLECA study. prospective cohort study on flecainide impact on persistent high premature ventricular contraction burden and induced cardiomyopathy

Received June 17, 2008; accepted September 4, 2008. Idiopathic ventricular arrhythmias (VAs) arising from the left ventricle (LV) are often accessible for catheter ablation from the aortic sinuses of Valsalva or adjacent to the mitral annulus (MA).1 The aortic and mitral valves are direct apposition and attach to an elliptical opening at the base of the LV known as the LV ostium.2 The VAs arising from this region are being increasingly recognized as targets for catheter ablation.3–7 This review describes the anatomic features of the LV ostium and the electrocardiographic, electrophysiological, and angiographic characteristics that are relevant to the mapping and ablation of these arrhythmias. The dominant central structure of the heart is the junction of the aorta with the LV. Fundamental for understanding idiopathic VAs arising near the aortic and mitral valves are 2 concepts: first, these arrhythmias arise from the LV ostium (Figure 1); and second, the LV ostium is covered by the aorto-ventricular membrane, a tough fibrous structure which is perforated by the aorta anteriorly and the mitral valve (MV) posteriorly (Figure 2). The anatomic concept of the LV ostium and its covering, the aorto-ventricular membrane, are based on the pioneering work of McAlpine.2 Figure 1. The left ventricular ostium (postero-cranial view). The left panel includes the aortic root with the right coronary sinus (R), left coronary sinus (L), and noncoronary sinus (N). In the right panel, the root of the aorta has been removed to demonstrate the elliptical ostium of the left ventricle (LV) with the junction of the right coronary cusp (RCC), left coronary cusp (LCC), and LV summit demonstrated. APM indicates anterior papillary muscle; LA, left atrium; LAFT, left anterior fibrous trigone; LFT, left fibrous trigone; L-RCC, the junction between the LCC and RCC; PPM, posterior papillary muscle; PSP, postero-superior …

Premature ventricular contraction detection and estimation of daily burden by an insertable cardiac monitor.

Resolution of new left bundle branch block and ventricular tachycardia with immunosuppressive therapy in a patient with cardiac sarcoidosis

Background/Objectives: Persistent high Premature Ventricular Contraction (PVC) burden (>10%) may result in PVC-induced cardiomyopathy. Current guidelines, supported by limited evidence, recommend flecainide for PVCs originating from the ventricular outflow tract (Class IIa). UNIFLECA is a prospective cohort study, aiming to assess the efficacy and safety of flecainide in PVC burden reduction in adults, irrespective of PVC origin, focusing secondarily on symptom relief and improvement of left ventricular ejection fraction (LVEF) in patients suffering from PVC-induced cardiomyopathy. Methods: Participants were adults with frequent PVCs, defined as PVC burden > 5%, confirmed by two 24 h Holter recordings taken at least one month apart, who denied catheter ablation treatment. Patients who were deemed ineligible for catheter ablation were also included. A total of 50 patients were screened and 35 were administered Flecainide, with dosage adjustment based on follow-up Holter results and QRS increases. Changes in PVC burden, LVEF, symptomatic status, along with treatment adherence, were evaluated. Results: In adults with frequent PVCs, flecainide led to a significant reduction in PVC burden, with a mean decrease of 76.2% in the first month, and 63.1% of patients achieving a PVC burden reduction greater than 80%. Conclusions: UNIFLECA contributes to the understanding of how personalized, non-interventional therapeutic modalities can be employed to manage PVCs, especially for patients unwilling to have or ineligible for ablation procedures.

Catheter ablation of ventricular arrhythmias (VA) from the papillary muscles (PM) is challenging due to limited catheter stability and contact on the PMs with their anatomic complexity and mobility. This study aimed to evaluate the effectiveness of cryoablation as an adjunctive therapy for PM VAs when radiofrequency (RF) ablation has failed. We evaluated a retrospective series of patients who underwent cryoablation for PM VAs when RF ablation had failed. The decision to switch to cryoablation was at the operator's discretion when intracardiac echocardiography (ICE) suggested that cryoablation might be more effective in achieving catheter stability and energy delivery. Sixteen patients underwent cryoablation of PM VAs between 2014 and 2016 after RF ablation was unsuccessful. VAs originated from the anterolateral left ventricle (LV) PM (six patients), posterolateral LV PM (six patients), and right ventricle PM (four patients). VAs were predominantly frequent premature ventricular complexes (PVCs); however, patients with sustained ventricular tachycardia and PVC-triggered VF were also represented. Fifteen of the 16 patients were treated with cryoablation; in one patient, a procedural complication with retrograde aortic access precluded treatment. In all patients treated with cryoablation, contact and stability was confirmed with ICE to be superior to the RF catheter, and there was acute and long-term elimination of VAs. Cryoablation is a useful adjunctive therapy in ablation of PM VAs, providing excellent procedural outcomes even when RF ablation has failed. Cryoablation catheters are less maneuverable than RF ablation catheters and care is required to avoid complications.

Role of intracardiac echocardiography for guiding ablation of tricuspid valve arrhythmias